

PubMed

Search

Display Settings: Abstract

[AJNR Am J Neuroradiol](#). 2012 Mar 1. [Epub ahead of print]

Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT Study).

[Seidl Z](#), [Vymazal J](#), [Mechl M](#), [Goyal M](#), [Herman M](#), [Colosimo C](#), [Pasowicz M](#), [Yeung R](#), [Paraniak-Gieszczyk B](#), [Yemen B](#), [Anzalone N](#), [Citterio A](#), [Schneider G](#), [Bastianello S](#), [Ruscalleda J](#).

Lekarska Fakulta, Neurologicka Klinika, Prague, Czech Republic; MRI Department, Na Homolce Hospital, Prague, Czech Republic; Department of Radiology, University Hospital Brno, Brno, Czech Republic; Department of Radiology, Seaman Family MR Centre, Foothills Medical Centre, Calgary, Alberta, Canada; Department of Radiology, University Hospital Olomouc, Olomouc, Czech Republic; Istituto di Radiologia, Policlinico "Agostino Gemelli," Rome, Italy; John Paul II Hospital, Krakow, Poland; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; NZOZ Slaskie Centrum Diagnostyki Obrazowej, "Helimed" Sp. Katowice, Poland; Hamilton Health Sciences Corporation, Henderson Campus, Hamilton, Ontario, Canada; Servizio di Neuroradiologia, Ospedale San Raffaele, Milan, Italy; Servizio di Neuroradiologia, Ospedale Niguarda Ca' Granda, Milan, Italy; Department of Diagnostic Radiology, Homburg University Hospital, Homburg/Saar, Germany; Fondazione Istituto Neurologico, Casimiro Mondino, Pavia, Italy; and Department of Neuroradiology, Hospital de la Santa Cruz y San Pablo-Barcelona, Barcelona, Spain.

Abstract

BACKGROUND AND PURPOSE: Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a more highly concentrated agent (1.0 mol/L). This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative evaluation of brain tumors.

MATERIALS AND METHODS: Adult patients with suspected or known brain tumors underwent 2 identical MR imaging examinations at 1.5T, 1 with gadobenate dimeglumine and

the other with gadobutrol, both at a dose of 0.1-mmol/kg body weight. The agents were injected in randomized order separated by 3-14 days. Imaging sequences and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for CNR and LBR.

RESULTS: One hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, "other" tumors, and "nontumor" (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol ($P < .0001$, all readers). Highly significant ($P < .0001$, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations ($\kappa = 0.414-0.629$). Significantly superior CNR and LBR were determined for gadobenate dimeglumine ($P < .019$, all readers).

CONCLUSIONS: Significantly greater morphologic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadobutrol at an equivalent dose.

PMID: 22383237 [PubMed - as supplied by publisher]

 **LinkOut - more resources**